Haemophilia Treatment Market Report and Forecast 2025-2034

The Haemophilia treatment market was valued at USD 14.84 Billion in 2024, driven by the increased rate of research and development to determine the appropriate and effective treatments and therapies across the 8 major markets. The market is anticipated to grow at a CAGR of 7.50% during the forecast period of 2025-2034 to achieve a value of USD 30.59 Billion by 2034.

Haemophilia Treatment Market Overview

Haemophilia is a rare inherited bleeding disorder in which the blood does not clot properly due to the absence or deficiency of clotting factors, typically factor VIII or IX. This condition leads to prolonged bleeding, spontaneous haemorrhages, and joint or muscle damage if untreated. Haemophilia is more common in males and is often diagnosed in early childhood. Treatment involves regular replacement therapy using clotting factor concentrates, either plasma-derived or recombinant. Newer therapies, including gene therapy and extended half-life factors, aim to reduce bleeding episodes, improve quality of life, and offer more convenient treatment regimens.

Haemophilia Treatment Market Growth Drivers

Innovative Prophylactic Therapies to Strengthen Market Growth

Advances in targeted therapies and rising preference for effective prophylactic treatments are significantly propelling the market. For instance, in March 2025, the US FDA approved Qfitlia (fitusiran), a first-in-class antithrombin-lowering therapy designed to prevent or reduce bleeding episodes in haemophilia A or B patients with or without inhibitors, aged 12 years or older. Based on ATLAS Phase 3 trial data, it demonstrated meaningful bleed protection across diverse haemophilia populations. This approval is expected to boost market expansion by offering a new, efficient treatment pathway and attracting investment in prophylactic research and development.

Emphasis on Gene Therapies to Drive Haemophilia Treatment Market Value

Gene therapy advancements and a rising demand for long-acting, durable solutions continue to shape the market landscape. For instance, in February 2025, CSL presented four-year data from its HOPE-B study on HEMGENIX® (etranacogene dezaparvovec-drlb), which confirmed the long-term safety and effectiveness of this single-infusion gene therapy for adults with haemophilia B. The results, shared at the 18th EAHAD Congress, highlighted sustained factor IX levels, reduced bleeding episodes, and elimination of routine prophylaxis. This news strengthens confidence in gene therapy's transformative role, likely accelerating its adoption, broadening eligible patient access, and positively influencing global market growth.

Haemophilia Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Application of Gene Therapies to Elevate Market Growth

In April 2024, the United States FDA approved Beqvez (fidanacogene elaparvovec-dzkt) by Pfizer for adults with moderate to severe haemophilia B. It targets patients on factor IX prophylaxis or those with serious bleeding histories, excluding those with specific antibodies. Priced at USD 3.5 million, it marks a significant leap in one-time gene therapy interventions. This approval is poised to redefine treatment dynamics by reducing the need for lifelong infusions, potentially lowering long-term healthcare costs and significantly enhancing patient compliance, thereby contributing to the premium pricing and revenue expansion within the global haemophilia treatment market.

Subcutaneous Therapies to Augment Haemophilia Treatment Market Value

In December 2024, Novo Nordisk secured FDA approval for Alhemo (concizumab-mtci), a once-daily subcutaneous prophylactic injection for patients aged 12 and older with haemophilia A or B with inhibitors. As the first subcutaneous treatment for this group, Alhemo offers an easier administration method through a prefilled pen and a fine 32-gauge needle. This innovation enhances convenience, reduces dependency on hospital-based intravenous infusions, and increases therapy adherence. As a result, it supports broader adoption, especially among paediatric and home-care patients, expanding the treatment market and fostering the development of self-administered options within the global haemophilia segment.

Advanced Research Collaborations to Bolster Haemophilia Treatment Market Size

In March 2024, ReciBioPharm and GeneVentiv Therapeutics initiated a strategic collaboration to develop GENV-HEM, a universal gene therapy designed for all haemophilia patients, including those with inhibitors. Manufacturing will take place at ReciBioPharm’s facility in Massachusetts, supporting the therapy’s journey from preclinical to Phase 1/2 trials. This alliance demonstrates the growing importance of CDMO partnerships in accelerating gene therapy pipelines. The advancement of GENV-HEM reflects the increasing demand for inclusive and durable therapeutic options, which is expected to bolster investment, enhance treatment efficacy, and positively influence the innovation trajectory within the haemophilia treatment market.

Development of Advanced Treatment Alternatives to Meet Growing Haemophilia Treatment Market Demand

In December 2024, India recorded a major scientific breakthrough with its first-in-human gene therapy using a lentiviral vector for Severe Haemophilia A. Conducted at CMC Vellore, all five patients achieved zero annualised bleeding rates with prolonged factor VIII production, eliminating the need for repeat infusions. Supported by the Department of Biotechnology, this marks a pivotal step in making advanced gene therapies accessible in low-resource settings. This development highlights the growing role of emerging markets in therapeutic innovation and is poised to drive regional and global market growth by promoting affordability, clinical confidence, and broader patient inclusion.

Haemophilia Treatment Market Segmentation

Haemophilia Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Disease Type

• Hemophilia A
• Severe
• Moderate
• Mild
• Hemophilia B
• Severe
• Moderate
• Mild
• Others

Market Breakup by Treatment Type

• Recombinant Coagulation Factor Concentrates
• Plasma Derived Coagulation Factor Concentrate
• Desmopressin
• Antifibrinolytics Agents
• Gene Therapy Products
• Replacement Therapy
• Recombinant
• Plasma Derived
• Others

Market Breakup by Patient

• Pediatric
• Adult

Market Breakup by Route of Administration

• Injectable
• Nasal
• Oral

Market Breakup by End User

• Hospitals
• Clinics
• Homecare Settings
• Others

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Haemophilia Treatment Market Share

Haemophilia A to Lead the Disease Type Segment

Haemophilia A is projected to hold the largest market share by disease type, primarily due to its higher prevalence compared to other types. Increased awareness, genetic screening, and diagnosis have contributed to early identification and management. The Centers for Disease Control and Prevention (CDC) estimates revealed that nearly 12 in 100,000 males are affected by the genetic disorder in the United States. Additionally, there are around 400 newborn males each year born with Haemophilia A in the United States. Market expansion is further driven by ongoing research and a strong pipeline of factor VIII therapies. Government support and improved healthcare access in developing regions are also boosting this segment. Continuous innovations, including gene therapy and long-acting recombinant factors, make Haemophilia A treatments more sustainable, positioning this segment as the key driver of future market value and development.

Replacement Therapy to Lead the Share by Treatment Type

Replacement therapy is expected to dominate the market share by treatment type, owing to its established clinical efficacy and widespread adoption. It directly addresses clotting factor deficiency, reducing the frequency and severity of bleeding episodes. Technological advancements in recombinant products and prophylactic regimens are improving patient outcomes, boosting market uptake. The growing availability of long-acting factors and increasing patient compliance support sustained growth. This segment benefits from increasing R&D investments and favourable reimbursement policies, making it central to the treatment paradigm and a major contributor to rising market demand and therapeutic innovation.

Adults Segment to Dominate the Haemophilia Treatment Market Segmentation by Patient

The adult patient segment is poised to lead the market by patient type, due to the cumulative burden of haemophilia and the need for long-term management. Many adults experience complications such as joint damage, which necessitate ongoing treatment, increasing the market value. Additionally, rising diagnosis rates in adulthood and greater access to advanced therapies enhance this segment’s dominance. Expanding adult patient registries and growing awareness campaigns are also contributing to improved healthcare engagement. The adult population is more likely to seek regular care, which drives consistent market demand and supports the long-term development of treatment solutions.

Intravenous Route Dominating the Haemophilia Treatment Market by Route of Administration

The intravenous route of administration remains the leading segment due to its reliability in delivering factor replacement and bypassing agents directly into the bloodstream. This method ensures rapid therapeutic action, especially during acute bleeding episodes. Its dominance is supported by its longstanding clinical use and compatibility with both on-demand and prophylactic therapies. While newer methods like subcutaneous delivery are emerging, intravenous administration continues to be the gold standard, particularly in severe cases. Robust clinical data, patient familiarity, and integration into home treatment regimens position this segment as a stable and growing contributor to overall market expansion.

Hospitals to Lead the Haemophilia Treatment Market Share by End User

Hospitals are expected to maintain their position as the dominant end user in the market, driven by the need for advanced medical supervision and infusion capabilities. These settings are essential for initiating treatment, managing severe cases, and conducting gene therapy. The presence of specialist haematology units and access to multidisciplinary care also enhance treatment outcomes. Inpatient services remain critical for acute and surgical interventions. With increasing hospital-based care in developing markets and continuous infrastructure improvements, this segment is projected to experience steady growth, reinforcing its central role in market development and healthcare delivery.

Haemophilia Treatment Market Analysis by Region

The United States is likely to retain the largest market share owing to its early adoption of gene therapies, robust insurance coverage, and the strong presence of biopharmaceutical innovators. High diagnosis rates and extensive clinical trials fuel market maturity. Germany and France are rapidly expanding due to structured haemophilia registries and government-backed reimbursement schemes. The United Kingdom’s NHS initiatives support equitable access. Meanwhile, Japan sees steady growth through strategic biosimilar use, and India is witnessing gradual market penetration via global NGO support. Italy and Spain show modest expansion, primarily in recombinant therapies. However, the U.S. continues to lead due to its advanced infrastructure and treatment innovation pipeline.

Leading Players in the Haemophilia Treatment Market

The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Novo Nordisk A/S

Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S is a global healthcare company renowned for its leadership in diabetes care, obesity treatment, and rare blood disorders. Within the haemophilia treatment market, the company offers a strong portfolio including recombinant factor VIII and IX products, such as Novoeight® and Rebinyn®. Novo Nordisk is committed to advancing treatment access and innovation through research into long-acting and gene therapy-based haemophilia solutions. Its deep expertise in biologics and sustained investment in rare disease therapies drive its influence in the global landscape.

Pfizer Inc

Established in 1849 and headquartered in New York City, United States, Pfizer Inc. is a multinational pharmaceutical leader with a diverse therapeutic portfolio. In the haemophilia treatment market, Pfizer offers key products like BeneFIX® (factor IX) and Xyntha® (factor VIII), which are widely used for replacement therapy in haemophilia B and A patients, respectively. Pfizer's strategic focus includes enhancing patient outcomes through longer-acting formulations and improved delivery systems. With a strong research and development backbone, Pfizer continues to explore gene therapy and personalised care models to broaden its impact in the haemophilia domain.

Bayer AG

Headquartered in Leverkusen, Germany, and founded in 1863, Bayer AG is a globally recognised life sciences company with a focus on healthcare and agriculture. In the field of haemophilia treatment, Bayer is known for its flagship recombinant factor VIII therapy, Kogenate®, and its successor, Jivi®, a long-acting treatment option for haemophilia A. Bayer’s research centres concentrate on innovative therapies that improve bleeding control and reduce treatment frequency. The company's global footprint and commitment to patient-centric solutions help solidify its role as a prominent player in the haemophilia treatment landscape.

CSL Behring

CSL Behring, a subsidiary of CSL Limited, was founded in 1904 and is headquartered in King of Prussia, Pennsylvania, United States. Specialising in biotherapies for rare and serious conditions, CSL Behring is a major contributor to the haemophilia treatment market. Its portfolio includes recombinant therapies such as Afstyla® and Idelvion®, addressing haemophilia A and B respectively, as well as plasma-derived treatments. The company is also actively involved in advancing gene therapy research. CSL Behring’s global reach and deep expertise in immunology and haematology position it as a leader in haemophilia care.

Key Questions Answered in the Haemophilia Treatment Market

• What was the haemophilia treatment market value in 2024?
• What is the haemophilia treatment market forecast outlook for 2025-2034?
• What is market segmentation based on disease type?
• What is market segmentation based on treatment type?
• What is market segmentation based on patient?
• What is market segmentation based on route of administration?
• What is market segmentation based on end users?
• What are the major factors aiding the haemophilia treatment market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major haemophilia treatment market trends?
• Which disease type will lead the market segment?
• Which treatment type will lead the market segment?
• Which patient will lead the market segment?
• Which route of administration will lead the market segment?
• Which end user will lead the market segment?
• Who are the key players involved in the haemophilia treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.